OpGen, Inc. (NASDAQ:OPGN) Files An 8-K Other Events

OpGen, Inc. (NASDAQ:OPGN) Files An 8-K Other Events
Item 8.01 Other Events.

A special meeting of the stockholders of OpGen, Inc, a Delaware corporation (the "Company"), was convened at 10:00 a.m. Eastern time on March 10, 2020 to consider matters related to the previously announced business combination with Curetis GmbH.

On March 10, 2020, the Company issued a press release announcing the adjournment of the special meeting until 10:00 am, Eastern time, on March 30, 2020 at the offices of Ballard Spahr LLP, 1909 K Street, NW, 12th Floor, Washington DC. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits


OPGEN INC Exhibit
EX-99.1 2 ex99x1.htm EXHIBIT 99.1 Exhibit 99.1       Curetis N.V. Shareholders Approve Planned Business Combination with OpGen   –   Key milestone achieved supporting planned business combination of Curetis Group and OpGen –      OpGen adjourns Special Meeting to March 30,…
To view the full exhibit click here

Story continues below

About OpGen, Inc. (NASDAQ:OPGN)

OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company’s high-resolution DNA tests are marketed under the Acuitas trade name.

An ad to help with our costs